Henry Schein's Quiet Comeback Is Getting Loud
Strong stock · S&P 500 · Henry Schein, Inc. (HSIC) · Analysis as of 2026-06-12
After years of navigating a historic cyberattack and a challenging macro backdrop, Henry Schein is posting its strongest sales growth in 15 quarters—and the market is starting to take notice. With a $750 million share repurchase program, double-digit EPS beats, and a technology segment accelerating fast, the story here is more compelling than most investors realize. The question isn't whether the fundamentals have improved—it's whether the street has caught up yet.
After enduring one of the most disruptive cyberattacks in healthcare distribution history, Henry Schein, Inc. has done something remarkable: it has not only recovered—it has accelerated.
The company's most recent quarterly results delivered a clear signal that the operational turnaround is gaining traction. Revenue came in at $3.37 billion, up 6.3% year-over-year, beating Wall Street's consensus estimate. More striking still, non-GAAP diluted EPS of $1.32 surpassed analyst expectations by 8.4%—the kind of beat that forces portfolio managers to revisit their models. Adjusted EBITDA reached $289 million, clearing the consensus bar by 8.6%. This was, by multiple measures, the strongest sales growth the company has delivered in approximately 15 quarters.
---
Fundamental Snapshot
| Metric | Value | |---|---| | Close Price | $81.25 | | P/E Ratio | 24.55x | | PEG Ratio | 1.73x | | TTM Revenue | ~$13.38B | | Q1 2026 Revenue Growth (YoY) | +6.3% | | Non-GAAP EPS Beat | +8.4% | | Full-Year 2026 EPS Guidance | $5.23–$5.37 | | Consensus Price Target | ~$85.64 |
---
The Dental Engine Is Firing. U.S. dental local internal growth reached 4.1% year-over-year in the latest quarter—more than triple the 1.3% that leading analysts had modeled. This outsized beat prompted BTIG to revise its stance on the stock, raising its price target to $100, citing the health of the broader dental market as a structural, not cyclical, tailwind. With aging populations, expanding dental insurance coverage, and post-pandemic demand normalization, the fundamentals underpinning Henry Schein's core business look durable.
Technology Is Becoming the Growth Engine. The Global Technology segment—encompassing cloud-based practice management platforms like Dentrix Ascend—posted 7.0% sales growth, reinforcing management's ambition to shift the portfolio toward higher-margin, recurring-revenue streams. High-growth, high-margin businesses now represent nearly 50% of total operating income, a milestone the company expects to surpass before the close of its current strategic cycle. This mix shift is the most underappreciated element of the Henry Schein investment thesis.
Capital Allocation Is Shareholder-Friendly. The Board authorized a $750 million share repurchase program, layered on top of a $500 million program launched earlier. With approximately $780 million still authorized for future repurchases and management executing buybacks at prices meaningfully below consensus targets, the company is deploying capital in a manner that signals internal conviction. Value creation initiatives target more than $200 million in annual operating income improvement, with a $125 million run rate targeted by year-end 2026.
Full-year guidance of 3%–5% sales growth and non-GAAP EPS of $5.23–$5.37 was maintained—a level of confidence that, given a strong Q1 beat, implies management may be setting a conservative bar.
---
Technical Picture
From a price action standpoint, Henry Schein's chart structure has improved materially. The stock is trading above both its 50-day moving average (~$74.66) and its 200-day moving average (~$73.16), a classic configuration that technicians interpret as confirmation of an emerging uptrend. The spread between the two moving averages is widening, consistent with building price momentum.
The 14-period RSI sits near 67—constructive territory that reflects genuine buying interest without yet signaling exhaustion. Broad moving-average composite indicators currently tilt strongly positive, suggesting that momentum across multiple time frames is aligned. The stock's move from the low-$70s toward the $81 range has been orderly rather than parabolic, which tends to indicate institutional accumulation rather than speculative excess.
---
The Takeaway
Henry Schein is not a turnaround story anymore—it is a growth story with a valuation that has yet to fully reflect the operational progress underway. A P/E of 24.5x against a recovering earnings trajectory, a $780 million repurchase authorization, and a technology segment compounding at high-single-digit rates present a profile worth watching closely. The market's consensus target of ~$85.64 implies meaningful upside from current levels, and recent analyst momentum suggests that number may soon move higher.
For investors focused on quality healthcare distribution franchises with improving fundamentals and technical confirmation, Henry Schein deserves a prominent position on the watchlist.
--- Disclaimer: This article is for educational purposes only and does not constitute financial advice. Please consult a qualified financial advisor before making any investment decisions.